Gyre Therapeutics, a San Diego-based biopharmaceutical company with 593 employees, focuses on developing F351 for treating NASH-associated fibrosis and has a pipeline through its indirect interest in Gyre Pharmaceuticals. The company went public on April 12, 2006, and also offers the drug ETUARY.
GYRE has been in the news recently: GYRE THERAPEUTICS is not directly mentioned in the provided information, but relevant entities like Neurocrine Biosciences, Inc. will present at the J.P. Morgan Healthcare Conference on January 13, 2025. Additionally, Parse Biosciences has enhanced its Evercode™ WT Mega Kit, enabling the analysis of up to 384 samples and 1 million cells in a single run, which supports high-throughput research.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
